Clinical Trials

Esomeprazole for Nausea and Vomiting Study:

Evaluation of the Efficacy of Esomeprazole in Suppressing Nausea and Vomiting in Patients Undergoing Chemotherapy for Breast Cancer

The common chemotherapy drugs used for breast cancer patients can cause feelings of nausea and may cause vomiting. Drugs called proton pump inhibitors (PPI) have been developed that stop stomach acid production. PPIs are approved to treat heartburn, ulcers, or gastroesophageal reflux disease (GERD). This study will look at a PPI called esomeprazole as a way to reduce the amount of nausea and vomiting seen in breast cancer patients receiving chemotherapy.

Patient Population:
  • Have Stage I, II, or III breast cancer.
  • Be receiving at least four cycles of anthracycline-based chemotherapy that may include: doxorubicin/cyclophosphamide (AC), 5-fluorouracil/ doxorubicin/cyclophosphamide (FAC), taxotere/doxorubicin/ cyclophosphamide (TAC), or 5-fluorouracil/epirubicin/cyclophosphamide (FEC) as agents for neoadjuvant or adjuvant chemotherapy.
  • Have no prior or current malignancies for which chemotherapy was utilized.
Patients will be randomized to receive either esomeprazole or placebo during the study:

Esomeprazole or placebo will be provided free of charge.

For more information or to have a patient screened, contact the Esomeprazole for Nausea and Vomiting Study Coordinator at 713-798-1986.